Headlands Technologies LLC raised its stake in shares of Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 277.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 21,017 shares of the company's stock after acquiring an additional 15,443 shares during the period. Headlands Technologies LLC's holdings in Surgery Partners were worth $445,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Cannell & Spears LLC bought a new position in Surgery Partners in the fourth quarter valued at about $324,000. Norges Bank purchased a new position in shares of Surgery Partners in the fourth quarter worth approximately $15,796,000. Pier Capital LLC grew its position in Surgery Partners by 15.9% during the fourth quarter. Pier Capital LLC now owns 382,493 shares of the company's stock valued at $8,097,000 after buying an additional 52,611 shares during the period. Vanguard Group Inc. raised its position in Surgery Partners by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 7,618,404 shares of the company's stock worth $161,282,000 after acquiring an additional 172,271 shares during the period. Finally, LPL Financial LLC raised its position in Surgery Partners by 22.4% in the fourth quarter. LPL Financial LLC now owns 16,749 shares of the company's stock worth $355,000 after acquiring an additional 3,062 shares during the period.
Insider Buying and Selling
In other news, insider Harrison R. Bane sold 56,315 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $25.64, for a total value of $1,443,916.60. Following the completion of the sale, the insider now owns 107,037 shares of the company's stock, valued at approximately $2,744,428.68. This represents a 34.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Marissa Brittenham sold 3,156 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $24.09, for a total value of $76,028.04. Following the sale, the insider now directly owns 63,408 shares in the company, valued at $1,527,498.72. This trade represents a 4.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 106,622 shares of company stock valued at $2,717,860 over the last three months. 2.30% of the stock is owned by company insiders.
Surgery Partners Trading Up 4.4 %
SGRY stock traded up $0.91 during mid-day trading on Wednesday, reaching $21.44. The company had a trading volume of 2,480,126 shares, compared to its average volume of 1,097,409. The firm has a 50 day moving average of $24.18 and a 200 day moving average of $24.92. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. Surgery Partners, Inc. has a 12 month low of $19.50 and a 12 month high of $33.97. The company has a market capitalization of $2.74 billion, a PE ratio of -44.67, a price-to-earnings-growth ratio of 19.21 and a beta of 2.40.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.38 by $0.01. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The company had revenue of $864.40 million for the quarter, compared to the consensus estimate of $828.09 million. On average, equities analysts predict that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the company. Royal Bank of Canada restated an "outperform" rating and issued a $35.00 price objective on shares of Surgery Partners in a research note on Tuesday, March 25th. Macquarie lowered their target price on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating on the stock in a report on Tuesday, March 11th. Finally, Bank of America initiated coverage on Surgery Partners in a report on Monday, December 16th. They set a "buy" rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, Surgery Partners presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.63.
Check Out Our Latest Stock Analysis on Surgery Partners
Surgery Partners Company Profile
(
Free Report)
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Read More
Before you consider Surgery Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.
While Surgery Partners currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
